Short Interest in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Rises By 5.6%

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) was the target of a significant growth in short interest in the month of March. As of March 31st, there was short interest totalling 32,250,000 shares, a growth of 5.6% from the March 15th total of 30,550,000 shares. Based on an average trading volume of 3,290,000 shares, the days-to-cover ratio is presently 9.8 days.

BioCryst Pharmaceuticals Trading Down 1.3 %

Shares of NASDAQ BCRX traded down $0.06 during mid-day trading on Tuesday, hitting $4.61. The company had a trading volume of 1,979,322 shares, compared to its average volume of 3,278,717. BioCryst Pharmaceuticals has a 1 year low of $4.45 and a 1 year high of $9.06. The stock's 50-day moving average price is $5.27 and its 200-day moving average price is $5.63. The company has a market capitalization of $950.35 million, a price-to-earnings ratio of -3.91 and a beta of 1.90.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last posted its earnings results on Monday, February 26th. The biotechnology company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.04). The company had revenue of $93.40 million during the quarter, compared to analyst estimates of $89.19 million. As a group, equities research analysts forecast that BioCryst Pharmaceuticals will post -0.68 earnings per share for the current year.

Analyst Ratings Changes

Separately, Needham & Company LLC restated a "buy" rating and issued a $12.00 target price on shares of BioCryst Pharmaceuticals in a research note on Wednesday, April 10th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $13.29.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its stake in BioCryst Pharmaceuticals by 15.4% during the fourth quarter. Vanguard Group Inc. now owns 17,763,720 shares of the biotechnology company's stock worth $106,405,000 after purchasing an additional 2,371,401 shares during the last quarter. BlackRock Inc. lifted its stake in BioCryst Pharmaceuticals by 4.5% during the second quarter. BlackRock Inc. now owns 15,495,703 shares of the biotechnology company's stock worth $109,090,000 after purchasing an additional 670,905 shares during the last quarter. Avoro Capital Advisors LLC lifted its stake in BioCryst Pharmaceuticals by 13.0% during the fourth quarter. Avoro Capital Advisors LLC now owns 13,050,000 shares of the biotechnology company's stock worth $78,170,000 after purchasing an additional 1,500,000 shares during the last quarter. State Street Corp lifted its stake in BioCryst Pharmaceuticals by 7.7% during the second quarter. State Street Corp now owns 12,263,969 shares of the biotechnology company's stock worth $86,338,000 after purchasing an additional 874,346 shares during the last quarter. Finally, Braidwell LP lifted its stake in BioCryst Pharmaceuticals by 6.6% during the fourth quarter. Braidwell LP now owns 5,718,477 shares of the biotechnology company's stock worth $34,254,000 after purchasing an additional 355,497 shares during the last quarter. 85.88% of the stock is currently owned by hedge funds and other institutional investors.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.